This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

5 Big Surprise Stock Winners of 2011

MILLBURN, N.J. (Stockpickr) -- 2011 is drawing to a close. While both professionals and do-it-yourself investors try to prognosticate the year ahead in advance, we're always dealt our fair share of surprises -- both good and bad.

With that in mind, let's take a look at the five biggest positive stock surprises and five biggest negative stock surprises of 2011, starting with the positive.

Also check out "5 Big Surprise Loser Stocks of 2011."

                   
 
2012 Stock Predictions and Outlook
Your one-stop shop for 2012 stock recommendations and market predictions.
 

Pharmasset: +467%

Overall, 2011 was not a good year for the biotech industry. The Amex Biotech Index has declined close to 20% so far in 2011. The Nasdaq Biotech Index and its corresponding ETF, iShares Nasdaq Biotech Index ETF (IBB), rose about 10% in the same period.

The difference in relative performance for those two indices was Pharmasset (VRUS), which represents approximately 11% of the Nasdaq Biotech Index but is not at all in the Amex Biotech Index. So it is fair to say that biotech ex-Pharmasset performed poorly in 2011.

According to the company's Web site, Pharmasset is "a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Our primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus ('HCV'). We currently have three product candidates and a series of preclinical candidates nearing preparation for clinical development."

The key product for the company is its treatment for hepatitis C. On Nov. 21, Gilead (GILD) agreed to buy Pharmasset for $137 per share. At the time, the stock was selling for $72.67. Prior to that deal being announced, Pharmasset shares had risen 234% on the year. (It shows up on a list of Five Drug Stock Winners of 2011.)

Pharmasset is definitely the woulda-coulda-shoulda stock of the year.

Ladenburg Thalman: +118%

Ladenburg Thalman (LTS) is an old boutique investment bank / brokerage firm based out of Miami. Given its size, relative obscurity and low stock price, Ladenburg Thalman is overlooked in the investment world.

Worth noticing, however, is that after 12 consecutive losing quarters, Ladenburg Thalman posted breakeven results for the first and second quarter of this year. This was achieved on the back of record revenue generation for this firm. The stock rose 18% in the first half of 2011.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,066.82 -12.75 -0.07%
S&P 500 1,999.69 +2.95 0.15%
NASDAQ 4,571.7360 +14.0410 0.31%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs